India’s Natco Pharma has announced a significant investment in South Africa’s 135-year-old pharmaceutical giant, Adcock Ingram. The R 4.2-billion deal will see Adcock Ingram become a privately-held entity co-owned by Natco and Bidvest, with Bidvest remaining the majority shareholder. The acquisition was approved by Adcock Ingram’s shareholders, with over 98% voting in favor of the deal. As a result, Adcock Ingram will be delisted from the Johannesburg Securities Exchange (JSE).
Adcock Ingram is a leading South African pharmaceutical company with a wide range of prescription, over-the-counter, consumer, and hospital products. The company has a long history, dating back to 1890, and has become a household name in South Africa. Despite its success, Adcock Ingram’s performance has been affected by the South African economy, and the company has been seeking ways to expand its presence beyond Southern Africa.
The partnership with Natco is expected to provide Adcock Ingram with access to new markets and revenue streams. Natco’s CEO, Rajeev Nannapaneni, stated that the deal will give Natco a well-established entry into the Southern African market and allow the company to tap into new revenue streams. Adcock Ingram’s CFO, Dorette Neethling, added that the partnership will enable the company to operate more efficiently and commercially, and will provide access to markets beyond Southern Africa.
The acquisition is also expected to benefit Adcock Ingram’s product lineup, with the company ruling out any immediate shake-up. However, the company may consider cutting brands if it makes economic sense. The partnership with Natco is expected to provide Adcock Ingram with the resources and expertise to expand its portfolio, particularly in the generics segment.
The deal has been welcomed by Adcock Ingram’s CEO, Andrew Hall, who stated that the partnership will provide South Africans with wider access to affordable medicines. The acquisition is expected to be completed soon, and will mark a significant milestone for both Natco and Adcock Ingram. With the partnership, Adcock Ingram will be able to leverage Natco’s research-focused and innovative approach to pharmaceuticals, and will be able to expand its presence in the African continent.